<DOC>
	<DOCNO>NCT00120406</DOCNO>
	<brief_summary>The Zilver® PTX™ Drug Eluting Vascular Stent indicate treatment symptomatic vascular disease above-the-knee femoropopliteal artery ( range 4 mm 9 mm reference vessel diameter ) lesions 7 cm long . The clinical trial stratify lesion length . The trial conduct 2 phase , Phase 1 enrol patient lesion le 7 cm long . Phase 2 trial include long lesion ( 14 cm long ) initiate upon approval Food Drug Administration ( FDA ) .</brief_summary>
	<brief_title>Evaluation Zilver PTX Drug-Eluting Stent Above-the-Knee Femoropopliteal Artery</brief_title>
	<detailed_description>The Zilver® PTX™ Drug Eluting Vascular Stent indicate treatment symptomatic vascular disease above-the-knee femoropopliteal artery ( range 4 mm 9 mm reference vessel diameter ) lesions 7 cm long . The above-the-knee femoropopliteal artery define superficial femoral artery ( SFA ) region popliteal artery plane femoral epicondyle . The clinical trial stratify lesion length . The trial conduct 2 phase , Phase 1 enrol patient lesion le 7 cm long . Phase 2 trial include long lesion ( 14 cm long ) initiate upon approval FDA . This study include 480 patient receive Zilver PTX stent Percutaneous transluminal angioplasty ( PTA ) 100 investigational site . Clinical data capture paper electronic case report form . Analyses include evaluation composite event-free survival rate patency rate 6- 12-month follow-up . Event-free survival define freedom major adverse event death , target lesion revascularization , target limb ischemia require surgical intervention ( bypass amputation toe , foot leg ) , surgical repair target vessel ( e.g. , dissection require surgery ) , worsen Rutherford classification 2 class class 5 6 . Patency assess duplex ultrasound patient . Patients may randomize one follow sub-studies : IVUS angiography 6 month ( stent patient ) , angiography 12 month , pharmacokinetic substudy ( Zilver PTX patient ) , ultrasound ( PTA patient ) . The trial also include provision patient experience PTA failure . These patient may randomize receive Zilver PTX stent bare Zilver stent .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Patient sign date informed consent . Patient 2 document stenotic occlude atherosclerotic lesion ( ro 14 cm long ) abovetheknee femoropopliteal artery , one limb , meet inclusion criterion none exclusion criterion . Patient de novo restenotic lesion ( ) &gt; 50 % stenosis document angiographically prior stent target lesion . Patient symptoms peripheral arterial disease classify Rutherford Category 2 great . Patient rest Ankle Brachial Index ( ABI ) &lt; 0.9 abnormal exercise ABI rest ABI normal . Patient incompressible artery ( ABI &gt; 1.2 ) must Toe Brachial Index ( TBI ) &lt; 0.8 . Patient agree return clinical status assessment duplex ultrasound 6 month , 12 month , 2 , 3 , 4 , 5 year . Patient agree return xrays 6 12 month . Patient agree return angiography 12 month . Patient agree contact telephone 1 , 3 , 9 , 18 month assess clinical status . Patient pregnant breastfeeding . Patient simultaneously participate another investigational drug device study . Patient significant stenosis occlusion inflow tract successfully treated procedure . Patient plan surgical interventional procedure within 30 day study procedure . Patient previous stenting target vessel . Patient antiplatelet and/or anticoagulant therapy contraindicate . Patient known hypersensitivity contraindication aspirin , antiplatelet medication , contrast dye , paclitaxel nitinol , opinion investigator , adequately premedicated . Patient lack least one patent vessel runoff &lt; 50 % stenosis throughout course . Patient untreated angiographicallyevident thrombus target lesion . [ Additional criterion may apply . ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Peripheral Arterial Disease ( PAD )</keyword>
	<keyword>Peripheral Vascular Disease</keyword>
	<keyword>Drug-Eluting Stent</keyword>
	<keyword>Drug-Coated Stent</keyword>
</DOC>